SCHEMBL15345966

SCHEMBL15345966

O=C(O)NC1CC1c1ccc(Nc2cccc(Cl)c2)nc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB4 P30926 1/20 0.50
CHRNA3 P32297 1/20 0.50
KDM1A O60341 1/20 0.46
MAOB P27338 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CNR2 P34972 9/20 0.42
EPHX2 P34913 1/20 0.41
CNR1 P21554 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
EGFR P00533 2/20 0.40
ERBB3 P21860 1/20 0.40
JAK2 O60674 1/20 0.40
ROCK2 O75116 1/20 0.40
MAP4K4 O95819 1/20 0.40
HCK P08631 1/20 0.40
ROS1 P08922 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15345967 1.00 CHRNB4 (0.50) CHRNB4CHRNA3KDM1AMAOBMEN1
SCHEMBL14882006 0.84 KDM1A (0.65) KDM1AMAOBCNR2EPHX2EGFR
SCHEMBL14882007 0.84 KDM1A (0.65) KDM1AMAOBCNR2EPHX2EGFR
SCHEMBL15355740 0.80 KDM1A (0.59) CHRNB4CHRNA3KDM1AMAOBCNR2
SCHEMBL1290434 0.80 KDM1A (0.59) CHRNB4CHRNA3KDM1AMAOBCNR2
SCHEMBL1290435 0.80 KDM1A (0.59) CHRNB4CHRNA3KDM1AMAOBCNR2
Hydrochloric Acid SCHEMBL1290665 0.79 KDM1A (0.57) CHRNB4CHRNA3KDM1AMAOBCNR2
Hydrochloric Acid SCHEMBL1290666 0.79 KDM1A (0.57) CHRNB4CHRNA3KDM1AMAOBCNR2
SCHEMBL12500007 0.78 CHRNB4 (0.46) CHRNB4CHRNA3KDM1AMAOBMEN1
SCHEMBL12500010 0.78 CHRNB4 (0.46) CHRNB4CHRNA3KDM1AMAOBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160000768-A1 CYCLOPROPYLAMINE INHIBITORS OF OXIDASES ORYZON GENOMICS S.A. (ES) 2016-01-07 US disclosed
US-9061966-B2 Cyclopropylamine inhibitors of oxidases ORYZON GENOMICS S.A. (ES) 2015-06-23 US disclosed
US-20130289076-A1 CYCLOPROPYLAMINE INHIBITORS OF OXIDASES ORYZON GENOMICS S.A. (ES) 2013-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160000768-A1 CYCLOPROPYLAMINE INHIBITORS OF OXIDASES PPOX, MAOB, MAOA CHRNB4 1351/4885CHRNA3 1323/4885KDM1A 828/4885
US-20130289076-A1 CYCLOPROPYLAMINE INHIBITORS OF OXIDASES PPOX, MAOB, MAOA CHRNB4 1351/4885CHRNA3 1323/4885KDM1A 828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.